Anavex stock crashes after EU rejection of Alzheimer's drug blarcamesine

Shares of Anavex Life Sciences (AVXL) plunged after the company withdrew its EU marketing application for blarcamesine, an experimental Alzheimer's treatment. The move followed a negative assessment from the European Medicines Agency (EMA), which questioned the drug's efficacy and safety data. Investors reacted sharply, sending the stock to a 52-week low on March 25, 2026. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion in December 2025, citing insufficient evidence of blarcamesine's benefits. Regulators flagged methodological flaws in the trials and noted the drug's limited effectiveness in patients without a specific SIGMAR1 gene mutation. Even after Anavex submitted long-term data for re-examination, the EMA maintained its stance, prompting the company to pull its application entirely.

The withdrawal marks a significant delay in Anavex's plans to commercialise blarcamesine. Earlier Phase 2b/3 results had shown promise, including a 36% improvement in Alzheimer's symptoms and a reduction in brain atrophy. However, the EMA's concerns suggest additional trials or complex analyses may now be required before resubmission. The setback has hit Anavex's stock hard, with shares tumbling nearly 30% to €2.55 on the day of the announcement. Over the past year, the stock has lost around 70% of its value, though analysts still rate it a 'Moderate Buy' with a 12-month target of $22—nine times its current price. The company's financial position remains stable, with $131 million in cash and no debt, enough to fund operations for over three years. The EMA's decision could also signal challenges ahead with the U.S. Food and Drug Administration (FDA). A rejection in Europe often foreshadows similar hurdles in the U.S., potentially limiting blarcamesine's global revenue prospects. Anavex's next steps will likely focus on addressing regulatory concerns, though the timeline for approval remains uncertain.

Anavex now faces a longer path to bringing blarcamesine to market, with the EMA's rejection adding pressure on future regulatory filings. The company's cash reserves provide a buffer, but the stock's steep decline reflects investor doubts about the drug's viability. All eyes will turn to the FDA's response, which could determine whether blarcamesine has a future in Alzheimer's treatment.